QUANTUM GENOMICS SAS-REGR (ALQGC.PA) Stock Overview
Europe - EPA:ALQGC - FR0011648971 - Common Stock
ALQGC.PA Key Statistics, Chart & Performance
The current stock price of ALQGC.PA is 0.0721 EUR. In the past month the price increased by 175.19%. In the past year, price decreased by -23.78%.
ALQGC.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 21.47 | 346.25B | ||
| 1ABBV.MI | ABBVIE INC | 21.34 | 344.13B | ||
| AMG.DE | AMGEN INC | 13.4 | 135.69B | ||
| GIS.DE | GILEAD SCIENCES INC | 15.54 | 128.80B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 25.27 | 94.65B | ||
| 1REGN.MI | REGENERON PHARMACEUTICALS | 12.65 | 52.80B | ||
| 1AE.DE | ARGENX SE | 94.23 | 43.22B | ||
| ARGX.BR | ARGENX SE | 94.23 | 43.22B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.84B | ||
| IDP.DE | BIOGEN INC | 9.39 | 19.01B | ||
| 1BIIB.MI | BIOGEN INC | 8.98 | 18.18B | ||
| 1NBIX.MI | NEUROCRINE BIOSCIENCES INC | 41.11 | 11.91B |
Related stock screener links
About ALQGC.PA
Company Profile
Quantum Genomics SA is a biopharmaceutical company, which engages in the development of therapies for cardiovascular diseases. The company is headquartered in Paris, Ile-De-France and currently employs 3 full-time employees. The company went IPO on 2009-07-28. The firm is a biopharmaceutical company dedicated to developing new therapies for unmet medical needs in cardiovascular disease, including high blood pressure and heart failure. Its main activity is in research and development of new therapies for the treatment of hypertension, BAPAI (Brain Aminopeptidase A Inhibitors) oriented in the field of cardiovascular diseases, especially high blood pressure and heart failure. The firm also co-develops products with academic teams, biotechnological research entities, and some of the pharmaceutical and bio-science companies. The firm is involved in four research programs. Quantum Genomics also collaborates with Center for Clinical Investigation 9201 APHP / INSERM of the Georges Pompidou European Hospital in Paris, among others.
Company Info
QUANTUM GENOMICS SAS-REGR
33 rue Marbeuf
Paris ILE-DE-FRANCE FR
Employees: 3
Phone: 33185347770
QUANTUM GENOMICS SAS-REGR / ALQGC.PA FAQ
What does ALQGC do?
Quantum Genomics SA is a biopharmaceutical company, which engages in the development of therapies for cardiovascular diseases. The company is headquartered in Paris, Ile-De-France and currently employs 3 full-time employees. The company went IPO on 2009-07-28. The firm is a biopharmaceutical company dedicated to developing new therapies for unmet medical needs in cardiovascular disease, including high blood pressure and heart failure. Its main activity is in research and development of new therapies for the treatment of hypertension, BAPAI (Brain Aminopeptidase A Inhibitors) oriented in the field of cardiovascular diseases, especially high blood pressure and heart failure. The firm also co-develops products with academic teams, biotechnological research entities, and some of the pharmaceutical and bio-science companies. The firm is involved in four research programs. Quantum Genomics also collaborates with Center for Clinical Investigation 9201 APHP / INSERM of the Georges Pompidou European Hospital in Paris, among others.
What is the current price of ALQGC stock?
The current stock price of ALQGC.PA is 0.0721 EUR. The price decreased by -1.77% in the last trading session.
Does QUANTUM GENOMICS SAS-REGR pay dividends?
ALQGC.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALQGC stock?
ALQGC.PA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is QUANTUM GENOMICS SAS-REGR worth?
QUANTUM GENOMICS SAS-REGR (ALQGC.PA) has a market capitalization of 5.00M EUR. This makes ALQGC.PA a Nano Cap stock.
Who owns QUANTUM GENOMICS SAS-REGR?
You can find the ownership structure of QUANTUM GENOMICS SAS-REGR (ALQGC.PA) on the Ownership tab.
ALQGC.PA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ALQGC.PA. When comparing the yearly performance of all stocks, ALQGC.PA is a bad performer in the overall market: 93.91% of all stocks are doing better.
ALQGC.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALQGC.PA. ALQGC.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
ALQGC.PA Financial Highlights
Over the last trailing twelve months ALQGC.PA reported a non-GAAP Earnings per Share(EPS) of -0.09. The EPS increased by 87.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -84.63% | ||
| ROE | -726.18% | ||
| Debt/Equity | 4.49 |
ALQGC.PA Forecast & Estimates
7 analysts have analysed ALQGC.PA and the average price target is 10.2 EUR. This implies a price increase of 14047.02% is expected in the next year compared to the current price of 0.0721.
For the next year, analysts expect an EPS growth of 6121.43% and a revenue growth 1744.53% for ALQGC.PA